# A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

> **NCT02106364** · PHASE3 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Peglispro
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT02106364
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-02
- **Primary completion:** 2015-11
- **Final completion:** 2016-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lilly's decision to cancel this trial is due to regulatory uncertainty in China.
- **Last updated:** 2016-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02106364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02106364, "A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02106364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*